Prima BioMed's "CANVAS" Clinical Trial Approved to Start in Korea

Prima BioMed Ltd (NASDAQ: PBMD ) is pleased to announce that the Korean Ministry of Food and Drug Safety has granted approval to start the CANVAS trial at several clinical sites in Korea. The Company expects that sites in Korea will be activated and patients will be able to